Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.

This case study highlights the importance of early diagnosis and treatment of acneiform eruptions associated with erlotinib in a 67-year-old male patient with non-small cell lung cancer to ensure patient compliance.

In this study, Deplanque et al. (2016) explored doxycycline's role in preventing erlotinib-induced folliculitis in patients with non-small-cell lung cancer, highlighting skin toxicity as a common side effect that can affect patient adherence to treatment.

This case report describes two patients who experienced loose anagen hairs and pili torti, resulting in nonscarring alopecia, potentially linked to erlotinib treatment for solid tumors.

This study suggests that erlotinib exacerbates inflammation in a mouse model of skin disease and that IL-1 inhibition could mitigate skin-related side effects of EGFR inhibitors.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

This report details a case of extensive leukotrichia induced by dasatinib in a patient with refractory chronic myelogenous leukemia.

This study screened synthesized pyridinecarboxamides for antitumor properties and found that many, particularly 5c and 7a, showed moderate in vitro activity against various human tumor cell lines.

This review examines the dermatologic effects of tobacco use and nicotine, noting potential benefits and drawbacks for various skin conditions, but reports no new clinical results.

This study found that neonatal administration of finasteride affected adult learning and memory in rats, enhancing object recognition but impairing aversive learning, with no effect on anxiety-like behavior.

This case presentation describes an adult with tinea capitis and related symptoms who was found to have a Trichophyton gypseum infection.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

In this study, researchers synthesized nine new nicotinamide derivative compounds and found that one, identified as N4, exhibited significant cytotoxic effects on MCF-7 breast cancer cells, while other derivatives demonstrated notable antibacterial, antifungal, and antibiofilm activities.

This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.

This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.

This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.